Pfizer withdrew Oxbryta (voxelotor), a conditionally approved oral therapy for SCD, saying its benefits don't outweigh risks.

Pfizer anticipates revenue growth, driven by oncology investments, M&A activities, and manufacturing optimization. See why ...

Pfizer withdrew its sickle cell disease treatment Oxbryta. Meanwhile, Senators introduce new bill to fortify health-care ...

Pfizer has divested a $3.3 billion stake in Haleon, reducing its holding in the British consumer healthcare company.

Healthcare professionals have been urged to stop supplying Oxbryta “immediately” after new data revealed “an unfavourable imbalance” of “fatal events” and “acute painful crises” in patients on the ...

The sickle cell treatment voxelotor (Oxbryta) has been withdrawn from all markets by the manufacturer Pfizer after a “higher than anticipated” number of deaths were reported and clinical evidence ...

Pfizer recalled Oxbryta and ended clinical trials over safety concerns, but sickle cell advocates are warning that stopping the drug abruptly could be dangerous.

Pfizer (NYSE:PFE) has reduced its ownership in the British consumer healthcare giant Haleon (NYSE:HLN) to 15% from 22.6% by ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price ...

Companies in the Consumer Goods sector have received a lot of coverage today as analysts weigh in on The Hershey Company (HSY – Research ...

The questions of drugs, real and spurious, has come up in the healthcare sector this week, with reports of drugs not meeting ...

The attack, which ended shortly after it began, capped a chaotic 24-hour period that began with Israel’s invading of Lebanon in pursuit of Hezbollah. Iran fired a barrage of ballistic missiles ...